MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Greenphire, LLC
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Peachtree Bioresearch Solutions Invests in Site Performance and Satisfaction with Greenphire’s Investigator Payment Software - CRO selects eClinicalGPS to improve accuracy, frequency, visibility and control of the site payment process - Peachtreebrs.com / Greenphire.com
Peachtree Bioresearch Solutions Invests in Site Performance and Satisfaction with Greenphire’s Investigator Payment Software

 

NewswireToday - /newswire/ - King of Prussia, PA, United States, 2017/12/12 - CRO selects eClinicalGPS to improve accuracy, frequency, visibility and control of the site payment process - Peachtreebrs.com / Greenphire.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Greenphire, the global leader in financial software for clinical trials, announced today that Peachtree Bioresearch Solutions has selected eClinicalGPS to improve the accuracy, frequency and visibility of its investigator payment strategy.

Peachtree Bioresearch Solutions is a full-service clinical research organization (CRO) that provides global clinical development services for emerging to mid-sized biotechnology, pharmaceutical, and medical device companies.

“The site relationship is no different than any other business partnership. Ensuring our investigators are paid in a timely fashion with full transparency is critical to performance and fostering a close, trusting relationship,” said Kristy Nichols, President, CEO and Co-Founder of Peachtree. “Partnership and performance are at the heart of our clinical development services. A top-quality site payment process ensures we continue to provide our clients with efficient and cost-effective services.”

There is an industry-wide movement to support monthly site payments. A recent study Greenphire conducted with the Society for Clinical Research Sites (SCRS) found that 84% of sites around the world would prefer payment in thirty days or less. Without a payment automation solution, increasing the frequency of site payments would have increased Peachtree’s operating costs by 400 percent.

“The competitive landscape of the CRO market is demanding that these teams do more with less, making it critical to eliminate resource draining functions such as clinical grant payments,” explained Dave Espenshade, Vice President of CRO Partnerships. “Our partners choose our solution to reduce the manual process, but quickly see additional positive impacts in site performance and financial control which is what sets our solution apart.”

eClinicalGPS is the only automated site payment solution that is designed with the site perspective in mind, which is why it continues to be the financial software of choice for CROs and sponsors focused on site satisfaction and performance. The site-centric approach provides the most comprehensive visibility and control, eliminating any ambiguities or re-work alternative methods require.

Greenphire’s implementation methodology for eClinicalGPS ensured the Peachtree team was up and running quickly, exceeding the team’s expectations.

CROs and sponsors looking to support monthly site payments and transform their investigator payment strategy to be efficient, transparent and controlled, contact Greenphire.

About Greenphire

Greenphire (greenphire.com) is the leader in global clinical trial payment automation. Greenphire’s best-in-class solutions optimize clinical trial performance by streamlining payment processes from sponsors and CROs to sites and patients. Greenphire’s ClinCard and eClinicalGPS solutions easily handle any type of trial design and complexity, resulting in more accurate and compliant payments globally for both sites and patients. The choice of industry leaders worldwide, Greenphire provides better performance and better data, resulting in better trials.

About Peachtree

Founded in 2008, Peachtree BioResearch Solutions, Inc. (peachtreebrs.com) is a Clinical Research Organization that specializes in providing clinical development services for emerging to mid-sized biotechnology, pharmaceutical, and medical device companies. With a highly-experienced clinical development team, Peachtree offers Clinical Project Management, Clinical Monitoring, Medical Monitoring, Biometrics (data management and statistical analysis), Technical Report Writing, Quality Assurance, and Clinical Staff Resourcing. Starting with one client at inception, Peachtree has grown its portfolio to over 65 clients providing services ranging from niche projects to full support.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Greenphire, LLC

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Peachtree Bioresearch Solutions Invests in Site Performance and Satisfaction with Greenphire’s Investigator Payment Software

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Press Office - Greenphire.com 
215-609-4378 / 215-609-4640 corporate[.]greenphire.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Greenphire, LLC securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Greenphire, LLC / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting
DSM Ignites New Strategic Initiative to Transform Global Animal Nutrition and Health
Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market
DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit  Limelon Advertising, Co.





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)